Login to Your Account

Clinic Roundup

Thursday, December 8, 2011
• Galena Biopharma Inc., of Lake Oswego, Ore., reported five-year efficacy data from an ongoing Phase II trial of NeuVax showing that the vaccine is safe and well tolerated, and demonstrated efficacy in preventing breast cancer recurrence in optimally dosed and boosted patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription